Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial

Kerry L. Lee, Gail Hafley, John Devens Fisher, Michael R. Gold, Eric N. Prystowsky, Mario Talajic, Mark E. Josephson, Douglas L. Packer, Alfred E. Buxton

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background - The Multicenter Unsustained Tachycardia Trial (MUSTT) was designed to evaluate an antiarrhythmic treatment strategy, including drugs and implantable defibrillators (ICDs), guided by electrophysiological (EP) testing. We performed several statistical analyses to assess the contribution of defibrillators to the observed treatment benefit. Methods and Results - First, the effects of defibrillators were indirectly examined by comparing the randomized treatment arms (EP-guided therapy versus no antiarrhythmic therapy) within subgroups that varied according to ICD usage. Use of ICDs increased during the trial; hence, the randomized treatments were compared according to date of enrollment. There were also site-specific differences in ICD use; hence, the randomized arms were compared within groups of sites defined by level of ICD use. There was a distinct "dose response" in relation to ICD use. Where ICD use was high, EP-guided therapy produced significant reductions in arrhythmic death or cardiac arrest (P<0.004). Where ICD use was low, there was no benefit of EP-guided therapy. Finally, outcomes of EP-guided therapy patients who received an ICD were directly compared with outcomes of other patients using the Cox proportional hazards model with receipt of an ICD as a time-dependent covariate. Adjusted for other prognostic factors, patients who received an ICD had risk reductions of >70% in arrhythmic death or cardiac arrest and >50% in total mortality (P<0.001 for both end points). Conclusions - The benefit of EP-guided antiarrhythmic therapy observed in MUSTT was due to improved outcomes among patients who received an ICD but not among patients who received antiarrhythmic drugs.

Original languageEnglish (US)
Pages (from-to)233-238
Number of pages6
JournalCirculation
Volume106
Issue number2
DOIs
StatePublished - Jul 9 2002
Externally publishedYes

Fingerprint

Implantable Defibrillators
Tachycardia
Mortality
Pharmaceutical Preparations
Defibrillators
Therapeutics
Heart Arrest
Anti-Arrhythmia Agents

Keywords

  • Antiarrhythmia agents
  • Defibrillation
  • Electrophysiology
  • Statistics
  • Tachyarrhythmias

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Lee, K. L., Hafley, G., Fisher, J. D., Gold, M. R., Prystowsky, E. N., Talajic, M., ... Buxton, A. E. (2002). Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial. Circulation, 106(2), 233-238. https://doi.org/10.1161/01.CIR.0000021920.73149.C3

Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial. / Lee, Kerry L.; Hafley, Gail; Fisher, John Devens; Gold, Michael R.; Prystowsky, Eric N.; Talajic, Mario; Josephson, Mark E.; Packer, Douglas L.; Buxton, Alfred E.

In: Circulation, Vol. 106, No. 2, 09.07.2002, p. 233-238.

Research output: Contribution to journalArticle

Lee, KL, Hafley, G, Fisher, JD, Gold, MR, Prystowsky, EN, Talajic, M, Josephson, ME, Packer, DL & Buxton, AE 2002, 'Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial', Circulation, vol. 106, no. 2, pp. 233-238. https://doi.org/10.1161/01.CIR.0000021920.73149.C3
Lee, Kerry L. ; Hafley, Gail ; Fisher, John Devens ; Gold, Michael R. ; Prystowsky, Eric N. ; Talajic, Mario ; Josephson, Mark E. ; Packer, Douglas L. ; Buxton, Alfred E. / Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial. In: Circulation. 2002 ; Vol. 106, No. 2. pp. 233-238.
@article{1ca80f9e56a14a8eb171ca903e0e46a4,
title = "Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial",
abstract = "Background - The Multicenter Unsustained Tachycardia Trial (MUSTT) was designed to evaluate an antiarrhythmic treatment strategy, including drugs and implantable defibrillators (ICDs), guided by electrophysiological (EP) testing. We performed several statistical analyses to assess the contribution of defibrillators to the observed treatment benefit. Methods and Results - First, the effects of defibrillators were indirectly examined by comparing the randomized treatment arms (EP-guided therapy versus no antiarrhythmic therapy) within subgroups that varied according to ICD usage. Use of ICDs increased during the trial; hence, the randomized treatments were compared according to date of enrollment. There were also site-specific differences in ICD use; hence, the randomized arms were compared within groups of sites defined by level of ICD use. There was a distinct {"}dose response{"} in relation to ICD use. Where ICD use was high, EP-guided therapy produced significant reductions in arrhythmic death or cardiac arrest (P<0.004). Where ICD use was low, there was no benefit of EP-guided therapy. Finally, outcomes of EP-guided therapy patients who received an ICD were directly compared with outcomes of other patients using the Cox proportional hazards model with receipt of an ICD as a time-dependent covariate. Adjusted for other prognostic factors, patients who received an ICD had risk reductions of >70{\%} in arrhythmic death or cardiac arrest and >50{\%} in total mortality (P<0.001 for both end points). Conclusions - The benefit of EP-guided antiarrhythmic therapy observed in MUSTT was due to improved outcomes among patients who received an ICD but not among patients who received antiarrhythmic drugs.",
keywords = "Antiarrhythmia agents, Defibrillation, Electrophysiology, Statistics, Tachyarrhythmias",
author = "Lee, {Kerry L.} and Gail Hafley and Fisher, {John Devens} and Gold, {Michael R.} and Prystowsky, {Eric N.} and Mario Talajic and Josephson, {Mark E.} and Packer, {Douglas L.} and Buxton, {Alfred E.}",
year = "2002",
month = "7",
day = "9",
doi = "10.1161/01.CIR.0000021920.73149.C3",
language = "English (US)",
volume = "106",
pages = "233--238",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial

AU - Lee, Kerry L.

AU - Hafley, Gail

AU - Fisher, John Devens

AU - Gold, Michael R.

AU - Prystowsky, Eric N.

AU - Talajic, Mario

AU - Josephson, Mark E.

AU - Packer, Douglas L.

AU - Buxton, Alfred E.

PY - 2002/7/9

Y1 - 2002/7/9

N2 - Background - The Multicenter Unsustained Tachycardia Trial (MUSTT) was designed to evaluate an antiarrhythmic treatment strategy, including drugs and implantable defibrillators (ICDs), guided by electrophysiological (EP) testing. We performed several statistical analyses to assess the contribution of defibrillators to the observed treatment benefit. Methods and Results - First, the effects of defibrillators were indirectly examined by comparing the randomized treatment arms (EP-guided therapy versus no antiarrhythmic therapy) within subgroups that varied according to ICD usage. Use of ICDs increased during the trial; hence, the randomized treatments were compared according to date of enrollment. There were also site-specific differences in ICD use; hence, the randomized arms were compared within groups of sites defined by level of ICD use. There was a distinct "dose response" in relation to ICD use. Where ICD use was high, EP-guided therapy produced significant reductions in arrhythmic death or cardiac arrest (P<0.004). Where ICD use was low, there was no benefit of EP-guided therapy. Finally, outcomes of EP-guided therapy patients who received an ICD were directly compared with outcomes of other patients using the Cox proportional hazards model with receipt of an ICD as a time-dependent covariate. Adjusted for other prognostic factors, patients who received an ICD had risk reductions of >70% in arrhythmic death or cardiac arrest and >50% in total mortality (P<0.001 for both end points). Conclusions - The benefit of EP-guided antiarrhythmic therapy observed in MUSTT was due to improved outcomes among patients who received an ICD but not among patients who received antiarrhythmic drugs.

AB - Background - The Multicenter Unsustained Tachycardia Trial (MUSTT) was designed to evaluate an antiarrhythmic treatment strategy, including drugs and implantable defibrillators (ICDs), guided by electrophysiological (EP) testing. We performed several statistical analyses to assess the contribution of defibrillators to the observed treatment benefit. Methods and Results - First, the effects of defibrillators were indirectly examined by comparing the randomized treatment arms (EP-guided therapy versus no antiarrhythmic therapy) within subgroups that varied according to ICD usage. Use of ICDs increased during the trial; hence, the randomized treatments were compared according to date of enrollment. There were also site-specific differences in ICD use; hence, the randomized arms were compared within groups of sites defined by level of ICD use. There was a distinct "dose response" in relation to ICD use. Where ICD use was high, EP-guided therapy produced significant reductions in arrhythmic death or cardiac arrest (P<0.004). Where ICD use was low, there was no benefit of EP-guided therapy. Finally, outcomes of EP-guided therapy patients who received an ICD were directly compared with outcomes of other patients using the Cox proportional hazards model with receipt of an ICD as a time-dependent covariate. Adjusted for other prognostic factors, patients who received an ICD had risk reductions of >70% in arrhythmic death or cardiac arrest and >50% in total mortality (P<0.001 for both end points). Conclusions - The benefit of EP-guided antiarrhythmic therapy observed in MUSTT was due to improved outcomes among patients who received an ICD but not among patients who received antiarrhythmic drugs.

KW - Antiarrhythmia agents

KW - Defibrillation

KW - Electrophysiology

KW - Statistics

KW - Tachyarrhythmias

UR - http://www.scopus.com/inward/record.url?scp=0037047116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037047116&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000021920.73149.C3

DO - 10.1161/01.CIR.0000021920.73149.C3

M3 - Article

C2 - 12105164

AN - SCOPUS:0037047116

VL - 106

SP - 233

EP - 238

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 2

ER -